Skip to main content

Neurodevelopmental Disorders Clinical Trials Centre (NDD-CTC)


We undertake clinical trials for the core symptoms and associated conditions of neurodevelopmental disorders in collaboration with industry partners, King’s clinical trials unitKHP clinical trials office, the NIHR Maudsley Biomedical Research Centre and the NIHR / Wellcome Trust King's Clinical Research Facility. 


Our focus

The NDD-CTC undertakes fully powered clinical trials of potential treatments identified in our clinical trials pipeline based on shiftability and other experimental studies within the department, and includes treatments for individuals with Autism spectrum conditions, Down syndrome, and intellectual disabilities.


Our Process

NDD-CTC Process


Step 1:

Find biomarker of neurodevelopmental disorder or comorbid condition shared by a group of people



Step 2:

Conduct 'shiftability study': target biomarker with dose of compound to test for response on biomarker



Step 3:

Does this make a biological difference? NO - STOP


Step 4:

Yes - move forward to 'Fast Fail' trial


Step 5:

Conduct 'Fast Fail' trial to test if we can maintain shift in the biomarker for ~weeks

Pill Crop2

Step 6:

Yes - full clinical trial should be done in people we know should respond



Step 7:
NDD-CTC conducts Phase II and III trials with ~hunderds of participant

Our Partners

NIHR Maudsley Biomedical Research Centre (BRC) logo

NIHR Maudsley Biomedical Research Centre

Project status: Ongoing